Image de couverture de livre

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Yaoli Cui, Ge Hu, Xue Han, Wei Li, Xianhuo Wang, Zhengzi Qian, Lanfang Li, Lihua Qiu, Shiyong Zhou, Huilai Zhang
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Hematological Oncology
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis
par: Bingyi Wang, et autres
Publié: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
par: Ganggang Wang, et autres
Publié: (2025)

Metabolic pathway‐based subtyping reveals distinct microenvironmental states associated with diffuse large B‐cell lymphoma outcomes
par: Xiaohui Wang, et autres
Publié: (2024)

Survival Benefit of Relmacabtagene Autoleucel Versus Usual Care in Relapsed/Refractory Follicular Lymphoma: A Matching‐Adjusted Indirect Analysis
par: Fenghua Gao, et autres
Publié: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
par: Rui Sun, et autres
Publié: (2026)

Peripheral T‐Cell Lymphoma: What's Next?
par: Sang Eun Yoon, et autres
Publié: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
par: Allison M. Bock, et autres
Publié: (2024)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
par: Alexandra Zduniak, et autres
Publié: (2025)

Identifying Clones in Myelodysplastic Syndromes by Using Single‐Cell RNA Sequencing
par: Roy Pollak, et autres
Publié: (2026)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
par: Jinyan Xiao, et autres
Publié: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Publié: (2026)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
par: Hazim S. Ababneh, et autres
Publié: (2024)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
par: Yue Zhao, et autres
Publié: (2025)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
par: Jiajie He, et autres
Publié: (2026)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
par: Tengfei Shi, et autres
Publié: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
par: Yan Li, et autres
Publié: (2025)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
par: Simone Ferrero, et autres
Publié: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
par: Chuanming Lin, et autres
Publié: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
par: Meirav Kedmi, et autres
Publié: (2024)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
par: J.T. Jutzi, et autres
Publié: (2025)

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
par: Domenico Albano, et autres
Publié: (2024)

Oncogenic IRF3 Signaling Promotes Diffused Large B‐Cell Lymphoma Proliferation by Cyclin D3/CDK4‐Dependent Cell Cycle Control
par: Bide Zhao, et autres
Publié: (2025)

Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
par: Robin Noel, et autres
Publié: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
par: Juliette Penichoux, et autres
Publié: (2025)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
par: Yutaka Shimazu, et autres
Publié: (2025)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
par: Theodoros P. Vassilakopoulos, et autres
Publié: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
par: Minna Harmanen, et autres
Publié: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
par: Inna Y. Gong, et autres
Publié: (2026)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
par: E. Silkenstedt, et autres
Publié: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
par: Pier Luigi Zinzani, et autres
Publié: (2025)

Treatment patterns, clinical outcomes and gene mutation characteristics of hepatitis B virus‐associated mantle cell lymphoma
par: Jiangfang Feng, et autres
Publié: (2024)

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma
par: Sara Ovejero, et autres
Publié: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
par: Akihiko Izumi, et autres
Publié: (2025)

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study
par: Yuma Nato, et autres
Publié: (2025)

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager
par: Daniele Caracciolo, et autres
Publié: (2026)

Differential Expression of CD79B, CD19, and PD‐L1 in de Novo and Transformed CD20‐Negative Large B‐Cell Lymphomas
par: Yuto Kaimi, et autres
Publié: (2026)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
par: Francesca Maria Quaglia, et autres
Publié: (2026)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
par: Yoshikazu Ikoma, et autres
Publié: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
par: Hazim S. Ababneh, et autres
Publié: (2024)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
par: Masahito Tokunaga, et autres
Publié: (2025)